Skip to main content

Peer Review reports

From: Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland

Original Submission
12 Feb 2017 Submitted Original manuscript
27 Feb 2017 Author responded Author comments - Karina Jahnz-Rozyk
Resubmission - Version 2
27 Feb 2017 Submitted Manuscript version 2
18 Jul 2017 Reviewed Reviewer Report - Mohsen Sadatsafavi
18 Nov 2017 Author responded Author comments - Karina Jahnz-Rozyk
Resubmission - Version 3
18 Nov 2017 Submitted Manuscript version 3
13 Jan 2018 Author responded Author comments - Karina Jahnz-Rozyk
Resubmission - Version 4
13 Jan 2018 Submitted Manuscript version 4
25 Feb 2018 Author responded Author comments - Karina Jahnz-Rozyk
Resubmission - Version 5
25 Feb 2018 Submitted Manuscript version 5
2 Mar 2018 Author responded Author comments - Karina Jahnz-Rozyk
Resubmission - Version 6
2 Mar 2018 Submitted Manuscript version 6
Publishing
6 Mar 2018 Editorially accepted
16 Mar 2018 Article published 10.1186/s12890-018-0610-z

You can find further information about peer review here.

Back to article page